Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.
Wenzel M, Hoeh B, Siech C, Koll F, Humke C, Groener D, Steuber T, Graefen M, Maurer T, Banek S, Chun FKH, Mandel P. Wenzel M, et al. Among authors: humke c. Eur J Nucl Med Mol Imaging. 2025 Jan 13. doi: 10.1007/s00259-025-07076-7. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 39804375
Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer.
Wenzel M, Hoeh B, Humke C, Welte M, Cano Garcia C, Siech C, Saad F, Karakiewcz PI, Tilki D, Steuber T, Graefen M, Traumann M, Chun FKH, Mandel P. Wenzel M, et al. Among authors: humke c. JBMR Plus. 2024 Nov 26;9(1):ziae157. doi: 10.1093/jbmrpl/ziae157. eCollection 2025 Jan. JBMR Plus. 2024. PMID: 39677923 Free PMC article.
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.
Wenzel M, Koll F, Hoeh B, Humke C, Reis H, Wild P, Steuber T, Graefen M, Tilki D, Sabet A, Gröner D, Chun FKH, Mandel P. Wenzel M, et al. Among authors: humke c. JCO Precis Oncol. 2024 Dec;8:e2400645. doi: 10.1200/PO-24-00645. Epub 2024 Dec 6. JCO Precis Oncol. 2024. PMID: 39642328
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis.
Wenzel M, Cano Garcia C, Humke C, Hoeh B, Steuber T, Tilki D, Merseburger AS, Kluth LA, Chun FKH, Mandel P. Wenzel M, et al. Among authors: humke c. Eur Urol Oncol. 2024 Aug 31:S2588-9311(24)00192-5. doi: 10.1016/j.euo.2024.08.007. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39218743 Free article.
[Sex-specific differences in surgical confidence: results of the Endo Workshop of the German Society of Residents in Urology 2022].
Siech C, Kluth LA, Konopka M, Reimann M, Plage H, Lichy I, Gerdes B, Kasperek J, Humke C, Marks P, Fisch M, Karakiewicz PI, Chun FKH, Schäfer T, Meyer CP, Kaulfuss JC. Siech C, et al. Among authors: humke c. Urologie. 2024 Nov;63(11):1122-1128. doi: 10.1007/s00120-024-02429-w. Epub 2024 Aug 27. Urologie. 2024. PMID: 39190147 Free PMC article. German.
45 results